Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 14, 2015, Pages 1584-1591

  Jagsi, Reshma ^a   Griffith, Kent A ^b   Kurian, Allison W ^a   Morrow, Monica ^a   Hamilton, Ann S ^a   Graff, John J ^a   Katz, Steven J ^a   Hawley, Sarah T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLACK PERSON; BREAST CANCER; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; COHORT ANALYSIS; ETHNIC DIFFERENCE; FAMILY HISTORY; FEMALE; GENETIC RISK; GENETIC SCREENING; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH SURVEY; HIGH RISK PATIENT; HISPANIC; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MINORITY GROUP; PATIENT ATTITUDE; PATIENT PREFERENCE; PATIENT WORRY; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RACE DIFFERENCE; UNITED STATES; AFRICAN AMERICAN; AGE; BREAST NEOPLASMS; CAUCASIAN; ETHNOLOGY; FAMILY; GENETICS; INTERPERSONAL COMMUNICATION; MIDDLE AGED; ODDS RATIO; PSYCHOLOGY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; BREAST NEOPLASMS; COMMUNICATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY; FEMALE; GENETIC TESTING; HEALTH PERSONNEL; HISPANIC AMERICANS; HUMANS; LOS ANGELES; MICHIGAN; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84933574451     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.5885     Document Type: Article

References (44)

1. Ford D, Easton D: The genetics of breast and ovarian cancer. Br J Cancer 72:805-812, Oct 1995
2. Kurian AW: BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 22:72-78, 2010
3. Wevers MR, Hahn DE, Verhoef S, et al: Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact. Patient Educ Couns 89:89-95, 2012
4. Schneider K, Zelley K, Nichols K, et al: Li-Fraumeni Syndrome, in Pagon R (ed): GeneReviews. Seattle, WA, University of Washington, Seattle, 1999
5. Daly MB, Pilarski R, Axilbund JE, et al: Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 12:1326-1338, 2014
6. Kurian AW, Hare EE, Mills MA, et al: Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32:2001-2009, 2014
7. Armstrong K, Micco E, Carney A, et al: Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 293:1729-1736, 2005
8. Peters N, Domchek SM, Rose A, et al: Knowledge, attitudes, and utilization of BRCA 1/2 testing among women with early-onset breast cancer. Genet Test 9:48-53, 2005
9. Fowler FJ: Improving Survey Questions: Design and Evaluation (Applied Social Research Methods). Thousand Oaks, CA, SAGE Publications, 1995
10. Katz SJ, Lantz PM, Paredes Y, et al: Breast cancer treatment experiences of Latinas in Los Angeles county. Am J Public Health 95:2225-2230, 2005
11. Hawley ST, Griggs JJ, Hamilton AS, et al: Decision involvement and receipt of mastectomy among racially and ethnically diverse patients with breast cancer. J Natl Cancer Inst 101:1337-1347, 2009
12. Zikmund-Fisher BJ, Smith DM, Ubel PA, et al: Validation of the subjective numeracy scale: Effects of low numeracy on comprehension of risk communications and utility elicitations. Med Decis Making 27:663-671, 2007
13. Willis GB: Cognitive Interviewing: A Tool for Improving Questionnaire Design. Thousand Oaks, CA, Sage Publications, Inc, 2005
14. Mauceri S: Cognitive interviewing: A tool for improving questionnaire design. Int J Soc Res Methodol 11:79-83, 2008
15. Dillman DA, Smyth JD, Christian LM: Internet, Mail, and Mixed-Mode Surveys: The Tailored Design Method (ed 3). Hoboken, NJ, John Wiley & Sons, 2009
16. Hamilton AS, Hofer TP, Hawley ST, et al: Latinas and breast cancer outcomes: Population based sampling, ethnic identity, and acculturation assessment. Cancer Epidemiol Biomarkers Prev 18: 2022-2029, 2009
17. Hughes C, Gomez-Caminero A, Benkendorf J, et al: Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Couns 32:51-62, 1997
18. Mogilner A, Otten M, Cunningham J, et al: Awareness and attitudes concerning BRCA gene testing. Ann Surg Oncol 5:608-612, 1998
19. Lerman C, Hughes C, Benkendorf JL, et al: Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Cancer Epidemiol Biomarkers Prev 8:361-367, 1999
20. Armstrong K, Calzone K, Stopfer J, et al: Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 9:1251-1254, 2000
21. Armstrong K, Weber B, Stopfer J, et al: Early use of clinical BRCA1/2 testing: Associations with race and breast cancer risk. Am J Surg Genet A 117A:154-160, 2003
22. Meiser B, Butow P, Barratt A, et al: Attitudes to genetic testing for breast cancer susceptibility in women at increased risk of developing hereditary breast cancer. J Med Genet 37:472-476, 2000
23. Kinney A, Croyle RT, Dudley WN, et al: Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: A survey of a large African-American kindred with a BRCA1 mutation. Prev Med 33:543-551, 2001
24. Peters N, Rose A, Armstrong K: The association between race and attitudes about predictive genetic testing. Cancer Epidemiol Biomarkers Prev 13:361-365, 2004
25. Lacour RA, Daniels MS, Westin SN, et al: What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 111:132-136, 2008
26. John EM, Miron A, Gong G, et al: Prevalence of pathogenic BRCA1 mutation carriers in 5 U.S. racial/ethnic groups. JAMA 298:2869-2876, 2007
27. Peterson EA, Milliron KJ, Lewis KE, et al: Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 11:79-87, 2002
28. Chaliki H, Loader S, Levenkron JC, et al: Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health 85:1133-1135, 1995
29. Lee SC, Bernhardt BA, Helzlsouer KJ: Utilization of BRCA1/2 genetic testing in the clinical setting. Cancer 94:1876-1885, 2002
30. Kausmeyer DT, Lengerich EJ, Kluhsman BC, et al: A survey of patients' experiences with the cancer genetic counseling process: Recommendations for cancer genetics programs. J Genet Couns 15:409-431, 2006
31. Rantala J, Platten U, Lindgren G, et al: Risk perception after genetic counseling in patients with increased risk of cancer. Hered Cancer Clin Pract 7:15, 2009
32. Rose AL, Peters N, Shea JA, et al: Attitudes and misconceptions about predictive genetic testing for cancer risk. Community Genet 8:145-151, 2005
33. Domchek SM, Eisen A, Calzone K, et al: Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 21:593-601, 2003
34. Risch HA, McLaughlin JR, Cole DE, et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694-1706, 2006
35. Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415, 1997
36. Malone KE, Daling JR, Thompson JD, et al: BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279:922-929, 1998
37. Whittemore AS, Gong G, John EM, et al: Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 13:2078-2083, 2004
38. Lerman C, Seay J, Balshem A, et al: Interest in genetic testing among first-degree relatives of patients with breast cancer. Am J Med Genet 57:385-392, 1995
39. Lodder L, Frets PG, Trijsburg RW, et al: Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. Am J Med Genet 119A:266-272, 2003
40. Hallowell N, Ardern-Jones A, Eeles R, et al: Men's decision-making about predictive BRCA1/2 testing: The role of family. J Genet Couns 14:207-217, 2005
41. Ardern-Jones A, Kenen R, Eeles R: Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care (Engl) 14:272-281, 2005
42. Offit K, Bradbury A, Storm C, et al: Gene patents and personalized cancer care: Impact of the myriad case on clinical oncology. J Clin Oncol 31: 2743-2748, 2013
43. Borzekowski DL, Guan Y, Smith KC, et al: The Angelina effect: Immediate reach, grasp, and impact of going public. Genet Med 16:516-521, 2014
44. Mouchawar J, Hensley-Alford S, Laurion S, et al: Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: A naturally-occurring experiment. Genet Med 7:191-197, 2005